StageZero Life Sciences
€0.02
18
+€0+0% Monday 06:00
Statistik
Harga Tertinggi Hari
-
Harga Terendah Hari
-
52M Tertinggi
-
52M Terendah
-
Volum
-
Volum Purata
-
Kapasiti Pasaran
3.36M
Nisbah P/E
-
Pendapatan Dividen
-
Dividen
-
Akan Datang
Pendapatan
12NovDijangka
EPS yang dijangka
N/A
EPS sebenar
N/A
Orang Lain Juga Mengikuti
Senarai ini berdasarkan senarai pantau orang di Stock Events yang mengikuti 61N1.F. Ini bukan cadangan pelaburan.
Peserta
Senarai ini adalah analisis berdasarkan peristiwa pasaran terkini. Ini bukan cadangan pelaburan.
Guardant Health
GH
Kapasiti Pasaran3.15B
Exact Sciences
EXAS
Kapasiti Pasaran11.4B
Fulgent Genetics
FLGT
Kapasiti Pasaran683.49M
Bionano Genomics
BNGO
Kapasiti Pasaran42.14M
Pacific Biosciences of California
PACB
Kapasiti Pasaran373.36M
Illumina
ILMN
Kapasiti Pasaran20.93B
Qiagen NV
QGEN
Kapasiti Pasaran10.16B
Thermo Fisher Scientific
TMO
Kapasiti Pasaran234.95B
Quest Diagnostics
DGX
Kapasiti Pasaran17.47B
Mengenai
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.
Show more...
CEO
Mr. James R. Howard-Tripp
Pekerja
40
Negara
CA
ISIN
CA8525403017
WKN
000A2QES5